Outlook Therapeutics
+$0.16 (+13.01%) Today
+$0.02 (+1.44%) As of 9:23 AM UTC after-hours
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell OTLK and other ETFs, options, and stocks.
About OTLK
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF.
CEO
C. Russell Trenary
Employees
9
Headquarters
Iselin, New Jersey
Founded
2010
OTLK Key Statistics
Market cap
311.72M
Price-Earnings ratio
—
Dividend yield
—
Average volume
1.55M
High today
$1.43
Low today
$1.22
Open price
$1.25
Volume
2.83M
52 Week high
$4.26
52 Week low
$0.9285
OTLK Earnings
-$0.12
-$0.08
-$0.04
$0.00
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Estimated
— per share
Actual
Expected Feb 14, Pre-Market